These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21940787)

  • 1. Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter.
    Kugel Desmoulin S; Wang L; Hales E; Polin L; White K; Kushner J; Stout M; Hou Z; Cherian C; Gangjee A; Matherly LH
    Mol Pharmacol; 2011 Dec; 80(6):1096-107. PubMed ID: 21940787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.
    Wilson MR; Hou Z; Yang S; Polin L; Kushner J; White K; Huang J; Ratnam M; Gangjee A; Matherly LH
    Mol Pharmacol; 2016 Apr; 89(4):425-34. PubMed ID: 26837243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.
    Cherian C; Kugel Desmoulin S; Wang L; Polin L; White K; Kushner J; Stout M; Hou Z; Gangjee A; Matherly LH
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):999-1011. PubMed ID: 23412628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.
    Desmoulin SK; Wang Y; Wu J; Stout M; Hou Z; Fulterer A; Chang MH; Romero MF; Cherian C; Gangjee A; Matherly LH
    Mol Pharmacol; 2010 Oct; 78(4):577-87. PubMed ID: 20601456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.
    Desmoulin SK; Wang L; Polin L; White K; Kushner J; Stout M; Hou Z; Cherian C; Gangjee A; Matherly LH
    Mol Pharmacol; 2012 Oct; 82(4):591-600. PubMed ID: 22740639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.
    Wang L; Desmoulin SK; Cherian C; Polin L; White K; Kushner J; Fulterer A; Chang MH; Mitchell-Ryan S; Stout M; Romero MF; Hou Z; Matherly LH; Gangjee A
    J Med Chem; 2011 Oct; 54(20):7150-64. PubMed ID: 21879757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.
    Wang L; Cherian C; Desmoulin SK; Polin L; Deng Y; Wu J; Hou Z; White K; Kushner J; Matherly LH; Gangjee A
    J Med Chem; 2010 Feb; 53(3):1306-18. PubMed ID: 20085328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
    Wang L; Wallace A; Raghavan S; Deis SM; Wilson MR; Yang S; Polin L; White K; Kushner J; Orr S; George C; O'Connor C; Hou Z; Mitchell-Ryan S; Dann CE; Matherly LH; Gangjee A
    J Med Chem; 2015 Sep; 58(17):6938-59. PubMed ID: 26317331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
    Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
    Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Characterization of Reduced Folate Carrier and Protein-Coupled Folate Transporter for Antifolates Accumulation in Non-Small Cell Lung Cancer Cells.
    Wang Y; Luo J; Bai M; Ma Z; Xu Y; Liu D; Jiang H; Ma S; Zhang S
    Drug Metab Dispos; 2024 Oct; 52(11):1332-1344. PubMed ID: 39261014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.
    Matherly LH; Hou Z; Gangjee A
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):1-15. PubMed ID: 29127457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.
    Matherly LH; Wilson MR; Hou Z
    Drug Metab Dispos; 2014 Apr; 42(4):632-49. PubMed ID: 24396145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase.
    Deis SM; Doshi A; Hou Z; Matherly LH; Gangjee A; Dann CE
    Biochemistry; 2016 Aug; 55(32):4574-82. PubMed ID: 27439469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.
    O'Connor C; Wallace-Povirk A; Ning C; Frühauf J; Tong N; Gangjee A; Matherly LH; Hou Z
    Sci Rep; 2021 Mar; 11(1):6389. PubMed ID: 33737637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.
    Hou Z; Matherly LH
    Curr Top Membr; 2014; 73():175-204. PubMed ID: 24745983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
    Ravindra M; Wilson MR; Tong N; O'Connor C; Karim M; Polin L; Wallace-Povirk A; White K; Kushner J; Hou Z; Matherly LH; Gangjee A
    J Med Chem; 2018 May; 61(9):4228-4248. PubMed ID: 29701475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.
    Desmoulin SK; Hou Z; Gangjee A; Matherly LH
    Cancer Biol Ther; 2012 Dec; 13(14):1355-73. PubMed ID: 22954694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier.
    Zhao R; Qiu A; Tsai E; Jansen M; Akabas MH; Goldman ID
    Mol Pharmacol; 2008 Sep; 74(3):854-62. PubMed ID: 18524888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.
    Deng Y; Zhou X; Kugel Desmoulin S; Wu J; Cherian C; Hou Z; Matherly LH; Gangjee A
    J Med Chem; 2009 May; 52(9):2940-51. PubMed ID: 19371039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
    Ravindra M; Wallace-Povirk A; Karim MA; Wilson MR; O'Connor C; White K; Kushner J; Polin L; George C; Hou Z; Matherly LH; Gangjee A
    J Med Chem; 2018 Mar; 61(5):2027-2040. PubMed ID: 29425443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.